Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Ca.HO4P.2H2O |
| Molecular Weight | 172.088 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.[Ca++].OP([O-])([O-])=O
InChI
InChIKey=XAAHAAMILDNBPS-UHFFFAOYSA-L
InChI=1S/Ca.H3O4P.2H2O/c;1-5(2,3)4;;/h;(H3,1,2,3,4);2*1H2/q+2;;;/p-2
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H3O4P |
| Molecular Weight | 97.9952 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Studies on the calcemic effect of intravenous secretin in humans. | 1975 Jun |
|
| Effects of terbutaline on force and intracellular calcium in slow-twitch skeletal muscle fibres of the rat. | 1999 Apr |
|
| Transient kinetic analysis of the 130-kDa myosin I (MYR-1 gene product) from rat liver. A myosin I designed for maintenance of tension? | 1999 Jul 30 |
|
| Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. | 1999 Nov |
|
| Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes. | 2000 Dec |
|
| D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | 2000 Dec 15 |
|
| Inactivation properties of human recombinant class E calcium channels. | 2000 Feb |
|
| Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase. | 2000 Feb 1 |
|
| alpha(1E) subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties. | 2000 Jan 1 |
|
| Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation. | 2000 Jan 15 |
|
| Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. | 2000 Jan 7 |
|
| A family of gamma-like calcium channel subunits. | 2000 Mar 24 |
|
| Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. | 2000 Nov |
|
| Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
| Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells. | 2000 Nov |
|
| Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. | 2000 Oct 15 |
|
| High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension. | 2000 Sep |
|
| ATP induces dephosphorylation of myosin light chain in endothelial cells. | 2000 Sep |
|
| Characterization of the human cysteinyl leukotriene 2 receptor. | 2000 Sep 29 |
|
| Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. | 2001 Apr 27 |
|
| Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. | 2001 Apr 7 |
|
| Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. | 2001 Aug 28 |
|
| Complement activation in factor D-deficient mice. | 2001 Dec 4 |
|
| The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
| Molecular and functional characterization of a family of rat brain T-type calcium channels. | 2001 Feb 9 |
|
| Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
| Analysis of the native quaternary structure of vanilloid receptor 1. | 2001 Jul 27 |
|
| Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. | 2001 Jun |
|
| Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D. | 2001 Jun |
|
| Cloning and characterization of a novel human histamine receptor. | 2001 Mar |
|
| Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. | 2001 Mar |
|
| Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001 Mar 2 |
|
| RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses. | 2001 Mar 27 |
|
| Activating mutations of the calcium-sensing receptor: management of hypocalcemia. | 2001 Nov |
|
| Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
| Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
| Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
| Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
| Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze. | 2001 Sep 7 |
|
| Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
| CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells. | 2002 Feb |
|
| Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. | 2002 Feb |
|
| Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
| Expression of functional CCR and CXCR chemokine receptors in podocytes. | 2002 Jun 15 |
|
| Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
| Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. | 2002 Sep |
|
| Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002 Sep 6 |
|
| Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension. | 2003 Jan |
|
| Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review. | 2014 Jul |
|
| Dietary interventions for mineral and bone disorder in people with chronic kidney disease. | 2015 Sep 16 |
Sample Use Guides
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:04:27 GMT 2025
by
admin
on
Mon Mar 31 18:04:27 GMT 2025
|
| Record UNII |
O7TSZ97GEP
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
40998-7
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
||
|
LOINC |
40999-5
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
||
|
LOINC |
42673-4
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7789-77-7
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
O7TSZ97GEP
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
C79566
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
C1505
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
C494366
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | Description: A white or almost white powder; odourless. Solubility: Practically insoluble in cold water and ethanol (~750 g/l) TS; soluble in dilute acids. Category: Tablet and capsule diluent. Storage: Calcium hydrogen phosphate should be kept in a well-closed container. Labelling: The designation on the container of Calcium hydrogen phosphate should state whether it is the dihydrate or the anhydrous form. Requirement: Calcium hydrogen phosphate contains not less than 30.9% and not more than the equivalent of 31.7% of calcium, Ca, calculated with reference to the ignited substance. | ||
|
1310463
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
ALTERNATIVE | |||
|
O7TSZ97GEP
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
104805
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
4496
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
100000092393
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
SUB23495
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
1311201
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | RxNorm | ||
|
DB14481
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
4448
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
DTXSID90872536
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
SUB11771MIG
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
PRIMARY | |||
|
1314331
Created by
admin on Mon Mar 31 18:04:27 GMT 2025 , Edited by admin on Mon Mar 31 18:04:27 GMT 2025
|
ALTERNATIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |